$CANSINOBIO (06185.HK)$ this share start to gets notice by investor  load at 36 .70 when fall back … earn some money sell at 42/-

$Hang Seng Index (800000.HK)$ concluded the day at 19,617, down 342 pts or 1.7%. $Hang Seng China Enterprises Index (800100.HK)$ sagged 131 pts or 2% to 6,601. $Hang Seng TECH Index (800700.HK)$ faded 137 pts or 3.5% to 3,824. The turnover aggregated $106.657 billion.
Techs slid as the market continued to be watchful of the Sino-US relations:
$BABA-W (09988.HK)$ dived 3.2% to $84.1.
$TENCENT (00700.HK)$ sank 1.9% to $338.4.
$MEITUAN-W (03690.HK)$ , $XIAOMI-W (01810.HK)$ , ...

Specifically, a second booster shot will be administered to people from high-risk groups, citizens older than 60, patients with chronic fundamental diseases and those with compromised immune systems. 
Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up. $CANSINOBIO (06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million. $RECBIO-B (02179.HK)$ , $INNOCARE (09969.HK)$ and ...

$CANSINOBIO (06185.HK)$ drop again..

Hong Kong-listed shares of $CANSINOBIO (06185.HK)$ extended gains in the afternoon session and rose as much as 18% shortly after the announcement was posted.
The notice said authorities should use multiple data points to accurately identify target groups for vaccination for the elderly.
$Hang Seng H-Share Index ETF (02828.HK)$ $Hang Seng Index (800000.HK)$ $China Concept Stocks (LIST2517.US)$ $HKEX Secondary Listings (LIST1304.HK)$ $AIM VACCINE (06660.HK)$ $Guotai CNI Vaccines and biotechnology ETF (159643.SZ)$

$CANSINOBIO (06185.HK)$ price is up on speculation cansino inhaler ( whole 1st Covid inhaler from china  with promising result ) will be approved by china body by  end of Q3 2022.
it will have great potential revenue once the inhaler version is approved because it is using the same vaccine approved by WHO.